Patterns of corticosteroid use among remdesivir and matched patients and associated clinical outcomes in hospitalized COVID-19 patients

被引:0
|
作者
Papic, Ivan [1 ]
Bistrovic, Petra [2 ]
Keres, Tatjana [3 ]
Hadziabdic, Maja Ortner [4 ]
Lucijanic, Marko [5 ,6 ,7 ]
机构
[1] Univ Hosp Dubrava, Pharm Dept, Zagreb, Croatia
[2] Univ Hosp Dubrava, Cardiol Dept, Zagreb, Croatia
[3] Univ Hosp Dubrava, Intens Care Dept, Zagreb, Croatia
[4] Univ Zagreb, Fac Pharm & Biochem, Ctr Appl Pharm, Zagreb, Croatia
[5] Univ Hosp Dubrava, Hematol Dept, Av Gojka Suska 6, Zagreb, Croatia
[6] Univ Zagreb, Sch Med, Internal Med Dept, Zagreb, Croatia
[7] Univ Zagreb, Sch Med, Zagreb 10000, Croatia
关键词
Remdesivir; corticosteroids; prognosis; dexamethasone; methylprednisolone; prednisone;
D O I
10.1080/14656566.2024.2320255
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
IntroductionWe aimed to investigate patterns of corticosteroid use and their relationship with remdesivir use and clinical outcomes in a large real-life cohort of COVID-19 patients treated in a tertiary-level institution.MethodsWe retrospectively analyzed a total of 1558 severe and critical COVID-19 patients, including 779 patients treated with remdesivir and 779 matched control patients.ResultsA total of 167 (10.7%) patients received none, 710 (45.6%) low, 539 (34.6%) high, and 142 (9.1%) very high corticosteroid doses. Patients treated with remdesivir had significantly longer exposure to corticosteroids, received higher average and maximal daily doses, and cumulative corticosteroid doses. In the multivariate analysis remdesivir use, lower cumulative comorbidity burden, higher severity of COVID-19 symptoms, and mechanical ventilation were recognized as mutually independent predictors of the use of higher corticosteroid doses. Higher corticosteroid doses were associated with significantly increased mortality.Among non-remdesivir treated patients, there was a U-shaped relationship between maximal daily corticosteroid dose and mortality. Among remdesivir treated patients gradual increase in mortality with increasing corticosteroid doses was observed.ResultsA total of 167 (10.7%) patients received none, 710 (45.6%) low, 539 (34.6%) high, and 142 (9.1%) very high corticosteroid doses. Patients treated with remdesivir had significantly longer exposure to corticosteroids, received higher average and maximal daily doses, and cumulative corticosteroid doses. In the multivariate analysis remdesivir use, lower cumulative comorbidity burden, higher severity of COVID-19 symptoms, and mechanical ventilation were recognized as mutually independent predictors of the use of higher corticosteroid doses. Higher corticosteroid doses were associated with significantly increased mortality.Among non-remdesivir treated patients, there was a U-shaped relationship between maximal daily corticosteroid dose and mortality. Among remdesivir treated patients gradual increase in mortality with increasing corticosteroid doses was observed.ConclusionPatterns of corticosteroid use differ regarding the use of remdesivir and may moderate its association with survival among severe and critical COVID-19 patients.
引用
收藏
页码:215 / 222
页数:8
相关论文
共 50 条
  • [31] The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19
    Whittington, Melanie D.
    Pearson, Steven D.
    Rind, David M.
    Campbell, Jonathan D.
    VALUE IN HEALTH, 2022, 25 (05) : 744 - 750
  • [32] Remdesivir modifies interferon response in hospitalized COVID-19 patients
    Murphy, Sarah L.
    Halvorsen, Bente
    Barratt-Due, Andreas
    Dyrhol-Riise, Anne Ma
    Aukrust, Pal
    Troseid, Marius
    Dahl, Tuva B.
    JOURNAL OF INFECTION, 2022, 85 (05) : 606 - 607
  • [33] Remdesivir, COVID-19, and Clinical Outcomes
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2022, 30 (02)
  • [34] Association of renal function with mortality among hospitalized patients treated with remdesivir for COVID-19
    Gonzalez Suarez, Maria Lourdes
    Mara, Kristin C.
    Rivera, Christina G.
    Chesdachai, Supavit
    Draper, Evan
    Razonable, Raymund R.
    PLOS ONE, 2024, 19 (06):
  • [35] The Impact of Early Antibiotic Use on Clinical Outcomes of Patients Hospitalized with COVID-19: A Propensity Score-Matched Analysis
    Duan, Yishan
    Ren, Jing
    Wang, Jing
    Wang, Suyan
    Zhang, Rui
    Zhang, Huohuo
    Hu, Jinrui
    Deng, Wen
    Li, Weimin
    Chen, Bojiang
    INFECTION AND DRUG RESISTANCE, 2024, 17 : 3425 - 3438
  • [36] Asthma among hospitalized patients with COVID-19 and related outcomes
    Lovinsky-Desir, Stephanie
    Deshpande, Deepti R.
    De, Aliva
    Murray, Laurie
    Stingone, Jeanette A.
    Chan, Angela
    Patel, Neha
    Rai, Nooralam
    DiMango, Emily
    Milner, Joshua
    Kattan, Meyer
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 146 (05) : 1027 - +
  • [37] ASSOCIATION OF DEMENTIA AND OUTCOMES AMONG HOSPITALIZED COVID-19 PATIENTS
    Vekaria, Pratikkumar
    Syed, Areej
    Anderson, Jeffrey
    Cornett, Brendon
    Bourbia, Amine
    Flynn, Michael
    Kashyap, Rahul
    Shah, Asif
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 131 - 131
  • [38] Remdesivir is Associated with Reduced Mortality in Patients Hospitalized for COVID-19 Not Requiring Supplemental Oxygen
    Mozaffari, Essy
    Chandak, Aastha
    Chima-Melton, Chidinma
    Kalil, Andre C.
    Jiang, Heng
    Lee, Eunyoung
    Der-Torossian, Celine
    Thrun, Mark
    Berry, Mark
    Haubrich, Richard
    Gottlieb, Robert L.
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (06):
  • [39] Treatment patterns and clinical outcomes of immunocompromised patients with COVID-19 receiving remdesivir in the inpatient setting in Japan
    Yoshida, Manami
    Taguchi, Nao
    Piao, Yi
    Gupta, Rikisha
    Peters, Jami
    Abdelghany, Mazin
    Chiang, Mel
    Wang, Chen-Yu
    Berry, Mark
    Yotsuyanagi, Hiroshi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2025, 31 (03)
  • [40] Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory State
    Libra, Alessandro
    Ciancio, Nicola
    Sambataro, Gianluca
    Sciacca, Enrico
    Muscato, Giuseppe
    Marino, Andrea
    Vancheri, Carlo
    Spicuzza, Lucia
    VIRUSES-BASEL, 2023, 15 (10):